What is Zacks Research’s Estimate for BAX Q1 Earnings?

Baxter International Inc. (NYSE:BAX) – Zacks Research reduced their Q1 2025 EPS estimates for shares of Baxter International in a research report issued to clients and investors on Thursday, March 13th. Zacks Research analyst I. Bandyopadhyay now anticipates that the medical instruments supplier will post earnings per share of $0.49 for the quarter, down from their previous estimate of $0.50. The consensus estimate for Baxter International’s current full-year earnings is $2.48 per share. Zacks Research also issued estimates for Baxter International’s Q2 2025 earnings at $0.60 EPS, Q3 2025 earnings at $0.66 EPS, Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.65 EPS, Q3 2026 earnings at $0.73 EPS, FY2026 earnings at $2.63 EPS and FY2027 earnings at $2.82 EPS.

Several other equities analysts have also commented on the stock. Barclays increased their target price on shares of Baxter International from $39.00 to $41.00 and gave the company an “overweight” rating in a report on Monday, March 10th. Argus raised shares of Baxter International from a “hold” rating to a “buy” rating in a report on Monday, February 24th. JPMorgan Chase & Co. cut their price target on shares of Baxter International from $38.00 to $36.00 and set a “neutral” rating on the stock in a report on Friday, February 21st. The Goldman Sachs Group began coverage on shares of Baxter International in a report on Wednesday, February 26th. They issued a “buy” rating and a $42.00 price target on the stock. Finally, Citigroup cut their price target on shares of Baxter International from $37.00 to $35.00 and set a “neutral” rating on the stock in a report on Wednesday, December 11th. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $38.56.

Baxter International Price Performance

BAX stock opened at $34.64 on Monday. The company has a debt-to-equity ratio of 1.31, a quick ratio of 1.09 and a current ratio of 1.43. Baxter International has a 52 week low of $28.34 and a 52 week high of $43.99. The firm’s fifty day moving average is $32.46 and its 200 day moving average is $33.95. The firm has a market cap of $17.72 billion, a P/E ratio of -27.06, a P/E/G ratio of 0.93 and a beta of 0.60.

Baxter International (NYSE:BAX) last released its earnings results on Thursday, February 20th. The medical instruments supplier reported $0.58 EPS for the quarter, beating the consensus estimate of $0.52 by $0.06. Baxter International had a negative net margin of 5.05% and a positive return on equity of 16.67%. The company had revenue of $2.75 billion for the quarter, compared to analyst estimates of $2.67 billion.

Institutional Investors Weigh In On Baxter International

Several institutional investors and hedge funds have recently modified their holdings of BAX. CoreFirst Bank & Trust purchased a new stake in shares of Baxter International in the 4th quarter worth about $26,000. Riverview Trust Co lifted its position in shares of Baxter International by 5,488.2% in the 4th quarter. Riverview Trust Co now owns 950 shares of the medical instruments supplier’s stock worth $28,000 after purchasing an additional 933 shares during the period. LRI Investments LLC lifted its position in shares of Baxter International by 60.8% in the 3rd quarter. LRI Investments LLC now owns 1,560 shares of the medical instruments supplier’s stock worth $59,000 after purchasing an additional 590 shares during the period. Bruce G. Allen Investments LLC lifted its position in shares of Baxter International by 247.3% in the 4th quarter. Bruce G. Allen Investments LLC now owns 2,622 shares of the medical instruments supplier’s stock worth $76,000 after purchasing an additional 1,867 shares during the period. Finally, CKW Financial Group lifted its position in Baxter International by 19.3% during the 4th quarter. CKW Financial Group now owns 2,625 shares of the medical instruments supplier’s stock valued at $77,000 after acquiring an additional 425 shares during the period. 90.19% of the stock is owned by hedge funds and other institutional investors.

Baxter International Announces Dividend

The business also recently announced a quarterly dividend, which will be paid on Tuesday, April 1st. Stockholders of record on Friday, February 28th will be given a $0.17 dividend. The ex-dividend date of this dividend is Friday, February 28th. This represents a $0.68 annualized dividend and a dividend yield of 1.96%. Baxter International’s dividend payout ratio is -53.13%.

Baxter International Company Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.